Safety and tolerability of empagliflozin in East Asian patients with type 2 diabetes: Pooled analysis of phase I–<scp>III</scp> clinical trials
Daisuke Yabe(Kansai Electric Power (Japan)), Yutaka Seino(Kansai Electric Power (Japan))
Cited by 40
Related Papers
GIP and GLP‐1, the two incretin hormones: Similarities and differences
|Journal of Diabetes Investigation|2010|707
Effects of ChREBP deficiency on adrenal lipogenesis and steroidogenesis
|Journal of Endocrinology|2021|11